MedMira Inc represents values of innovation, integrity, and commitment to global health. The company's corporate philosophy revolves around developing and delivering innovative, rapid diagnostic solutions that improve healthcare outcomes worldwide. MedMira Inc's dedication to scientific excellence, stringent quality control, and customer satisfaction has positioned them as a trusted leader in the diagnostic industry. With a focus on precision and accuracy, MedMira Inc strives to provide diagnostic tools and technologies that surpass industry standards, ultimately enhancing patient care and contributing to better healthcare practices globally.

MedMira Inc is primarily present in multiple countries and regions worldwide. The company has a global presence, with its products and services being recognized in North America, Europe, Asia, and Africa. MedMira Inc has successfully established a strong foothold in the United States and Canada, where it continues to expand its market share. Additionally, the company has made significant strides in penetrating international markets, including Europe and Asia. With its commitment to delivering innovative healthcare solutions, MedMira Inc aims to provide its products to healthcare professionals and customers globally.

MedMira Inc. has achieved several significant milestones in its history. Firstly, the company developed and commercialized its rapid HIV test, the Reveal G4, which offers quick and accurate results in just three minutes. This breakthrough in technology has helped in detecting HIV infections and preventing their spread. Additionally, MedMira Inc. received regulatory approvals from the World Health Organization (WHO), the U.S. Food and Drug Administration (FDA), and the European Commission (CE Mark) for its innovative product. These milestones have positioned MedMira Inc. as a leader in the field of rapid diagnostics and underscore its commitment to improving global healthcare.

MedMira Inc is a Canadian biotech company specializing in the development and commercialization of rapid diagnostic testing solutions. Founded in 1993, MedMira has gained global recognition for its innovative technologies in infectious disease detection, particularly with regards to HIV and hepatitis C. With a commitment to advancing healthcare accessibility, MedMira has developed a range of rapid testing products that deliver accurate results in a matter of minutes. These tests have found applications in both clinical and non-clinical settings, including hospitals, clinics, blood banks, and research laboratories. MedMira Inc continues to be at the forefront of diagnostic testing solutions, driving advancements in the field of healthcare.

The main competitors of MedMira Inc in the market include companies like Abbott Laboratories, OraSure Technologies, and Chembio Diagnostics.

MedMira Inc is primarily active in the medical diagnostics and biotechnology industries.

MedMira Inc, a leading medical technology company, operates on a business model focused on the development and commercialization of rapid diagnostic solutions. Through extensive research and innovation, MedMira creates advanced tests for infectious diseases, including HIV, hepatitis, and other sexually transmitted infections. These tests are designed to provide accurate and reliable results in a shorter timeframe, enabling healthcare professionals to make informed decisions swiftly. MedMira Inc collaborates with healthcare providers, governments, and distributors worldwide to ensure the widespread availability and accessibility of their diagnostic solutions, ultimately improving patient outcomes and contributing to global health initiatives.

Az KGV a MedMira esetében jelenleg nem számítható ki.

A MedMira számára az aktuális KUV nem számítható ki.

Az AlleAktien Minőségi Score MedMira esetében 5/10.

A MedMira esetében jelenleg nem számítható ki az árbevétel.

A nyereséget jelenleg nem lehet kiszámítani a MedMira számára.

MedMira Inc is an internationally active biotechnology company from Canada, specializing in the development, manufacture, and marketing of diagnostic rapid tests for infectious diseases. The company's business model is based on the production and sale of various products used in different areas of healthcare. The broad product portfolio of MedMira includes rapid tests for professional use in clinical laboratories as well as for home use. The company's various divisions focus on the production of diagnostic tests for HIV, hepatitis B and C, syphilis, and other infectious diseases. MedMira produces both individual test kits for direct use by medical personnel and complex systems for use in clinical facilities. The company's focus is on reducing the cost of infection testing without compromising on quality and reliability. An important part of MedMira's business model is research and development of new products. The constant work on new testing methods and technologies allows the company to constantly stay up to date with its products and stand out from the competition. In addition to selling rapid tests, MedMira also offers training and consultations for medical personnel. The goal is to improve understanding of infectious diseases and the importance of early detection tests. Through close collaboration with international development and distribution partners, MedMira has access to various markets and can offer its products worldwide. The company strongly focuses on the needs of end users and providing customized solutions. Overall, MedMira's successful business model is based on a combination of high-quality production capacity, efficient distribution and marketing, and continuous research and development. The company stands for high ethical responsibility and aims to contribute to the improvement of global health.

A(z) MedMira évente alkalommal oszt ki 0 CAD összegű osztalékot.

A MedMira esetében jelenleg nem lehet kiszámítani a osztalékot, vagy a vállalat nem fizet osztalékot.

A(z) MedMira ISIN kódja: CA58501R1029.

A MedMira WKN-je 932414.

Az MedMira tőzsdei rövidítése MIR.V.

Az elmúlt 12 hónapban a(z) MedMira osztalékot fizetett összegben. Ez körülbelül osztalékhozamnak felel meg. A következő 12 hóban a(z) MedMira várhatóan 0 CAD összegű osztalékot fog fizetni.

A(z) MedMira jelenlegi osztalékhozama .

A(z) MedMira negyedévente fizet osztalékot. Az osztalékokat a következő hónapokban osztják ki: .

A MedMira az elmúlt 0 évben minden évben fizetett osztalékot.

A következő 12 hónapban 0 CAD összegű osztalékra számítanak. Ez 0 % osztalékhozamnak felel meg.

A(z) MedMira a(z) 'Egészség' szektorhoz van besorolva.

Az utolsó, MedMira által 2024. 09. 20.-án/én fizetett 0 CAD összegű osztalék megszerzéséhez a részvénynek az ex-nap előtti 2024. 09. 20.-nál kellett lennie a portfóliódban.

Az utolsó osztalék kifizetése 2024. 09. 20. időpontban történt.

2023 évben a MedMira 0 CAD összegű osztalékot fizetett ki.

Az MedMira osztalékait CAD fizeti ki.